Switchable magneto-plasmonic contrast agents and molecular imaging technologies
One of 2 projects Taiyo tracks in Austria, France, Spain.
Source: EU Funding & Tenders Portal
SWIMMOT will establish the scientific and technological basis for a radically new technique for in vivo molecular imaging based on a switchable contrast agent (CA) and corresponding optical imaging technology. Our CA will be based on novel magnetic core / plasmonic gold shell nanorods with specifically engineered biofunctional shells. We will develop a new magneto-plasmonic imaging technique based
- Status
- Closed
- Sector
- Government
- Location
- Austria
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Switchable magneto-plasmonic contrast agents and molecular imaging technologies
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | SWIMMOT will establish the scientific and technological basis for a radically new technique for in vivo molecular imaging based on a switchable contrast agent (CA) and corresponding optical imaging technology. Our CA will be based on novel magnetic core / plasmonic gold shell nanorods with specifically engineered biofunctional shells. We will develop a new magneto-plasmonic imaging technique based on magnetic excitation and plasmonic signal generation to realise multimodal optical coherence tomography / photoacoustic imaging modes. The magneto-plasmonic imaging technique will turn our CA on and off, which will allow complete removal of the imaging background. This discrimination of the background from the CA signal will yield ultra-high contrast molecular imaging. In addition, SWIMMOT, for the first time, will enable in vivo quantification of soluble biomarker concentrations and visualisation down to cellular resolution, which holds the potential to revolutionise molecular imaging and to surpass all current technological paradigms. These science and technology breakthroughs will enable detection of previously inaccessible in vivo physiology and molecular events, and elucidation of until now poorly understood biological mechanisms through studies in model organisms. This will in turn contribute to a better understanding of normal processes and disease pathogenesis. Thus, SWIMMOT will ultimately lead to earlier disease diagnostics for humans and to the development of new therapy concepts (including drugs). We will apply the SWIMMOT technology for diabetes research and will demonstrate its breakthrough potential for uncovering new biomolecular mechanisms in zebrafish model organisms. |
Location
Country | Austria |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Government |
Article published date | 2025-10-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
